research use only

CTEP (RO4956371) GluR antagonist

Name: CTEP (RO4956371)
Brand: Selleck Chemicals
SKU: S2861
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S2861

CTEP (RO4956371) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, and it shows >1000-fold selectivity over other mGlu receptors.

Chemical Structure

Molecular Weight: 391.77

Jump to

Quality Control

Batch: Purity: 99.84%

99.84

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE)
Other GluR Inhibitors	pomaglumetad (LY404039) O-Phospho-L-serine (S)-Glutamic acid Capric acid MPEP VU 0364439 ADX-47273 Xanthurenic Acid SIB 1757 L-Glutamic acid monosodium salt

Solubility

In vitro
Batch:

DMSO : 78 mg/mL (199.09 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	391.77	Formula	C₁₉H₁₃ClF₃N₃O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	871362-31-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC1=C(N=C(N1C2=CC=C(C=C2)OC(F)(F)F)C)C#CC3=CC(=NC=C3)Cl

Mechanism of Action

Targets/IC₅₀/Ki	mGlu5 2.2 nM
In vitro	In HEK293 cells stably expressing human mGlu5, CTEP (RO4956371) inhibits quisqualate-induced Ca²⁺ mobilization with an IC50 of 11.4 nM and [³H]IP accumulation with an IC50 of 6.4 nM. It also inhibits the constitutive activity of human mGlu5 by approximately 50% with an IC50 of 40.1 nM.
In vivo	CTEP (RO4956371) is significantly active at doses of 0.1 mg/kg and 0.3 mg/kg in treatment of anxiety in mouse. It significantly increases drinking time at doses of 0.3 mg/kg and 1.0 mg/kg in the Vogel conflict drinking test in rat, whereas it has no effect at lower doses. The half-life of this compound (oral) is 18 h, and the B/P ratio based on total drug concentrations in plasma and whole brain homogenates is 2.6 in mice. After single oral doses of 4.5 and 8.7 mg/kg formulated as microsuspension in a saline/Tween vehicle administrated to adult C57BL/6 mice, it is rapidly absorbed and achieves close to maximal exposure after approximately 30 min. Chronic administration in adult mice with a dose of 2 mg/kg p.o. every 48 h for 2 months reaches a minimal brain exposure of 240 ng/g. It fully displaces [³H]ABP688 in mouse brain regions known to express mGlu5, and 50% displacement is achieved with doses producing an average compound concentration of 77.5 ng/g measured in whole brain homogenate. At 2 mg/kg p.o. bid, it achieves uninterrupted mGlu5 occupancy per 48 hours in mice. Treatment with this compound (2 mg/kg p.o.) corrects elevated hippocampal long-term depression, excessive protein synthesis, and audiogenic seizures in the Fmr1 knockout mouse.
References	[1] https://pubmed.ncbi.nlm.nih.gov/21849627/ [2] https://pubmed.ncbi.nlm.nih.gov/22500629/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05915208	Recruiting	Histiocytosis\|Langerhans Cell Histiocytosis\|Erdheim-Chester Disease\|Rosai Dorfman Disease\|Xanthogranuloma\|Malignant Histiocytoses	University of Alabama at Birmingham	September 1 2022	--
NCT02424916	Completed	Metastatic Melanoma	Nantes University Hospital\|UMR892	May 26 2015	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Do you have advice for its administration in mouse via injection?

Answer:
The IP formula for S2861 is 2% DMSO+40% PEG300+2% Tween-80 +H2O.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):